Latigo saddles up with $150M to spur non-opioid pain drugs through the clinic
Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance its pipeline of non-opioid pain management drugs.

Mar 15, 2025 0
Mar 8, 2025 0
Mar 15, 2025 0
Mar 16, 2025 0
Mar 16, 2025 0
Mar 16, 2025 0
Mar 17, 2025 0
Feb 9, 2025 0
Feb 9, 2025 0
Feb 9, 2025 0
Feb 9, 2025 0
Mar 17, 2025 0
Mar 17, 2025 0
Mar 17, 2025 0
Mar 14, 2025 0
Or register with email
Feb 9, 2025 0
Feb 10, 2025 0
Feb 11, 2025 0
Feb 9, 2025 0
Feb 9, 2025 0
Feb 13, 2025 0
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.